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Case fatality of COPD exacerbations: a
meta-analysis and statistical modelling
approach
M. Hoogendoorn*, R.T. Hoogenveen#, M.P. Rutten-van Mo¨lken*, J. Vestbo",+,1 and
T.L. Feenstra#,e
ABSTRACT: The aim of our study was to estimate the case fatality of a severe exacerbation from
long-term survival data presented in the literature.
A literature search identified studies reporting o1.5 yr survival after a severe chronic
obstructive pulmonary disease (COPD) exacerbation resulting in hospitalisation. The survival
curve of each study was divided into a critical and a stable period. Mortality during the stable
period was then estimated by extrapolating the survival curve during the stable period back to the
time of exacerbation onset. Case fatality was defined as the excess mortality that results from an
exacerbation and was calculated as 1 minus the (backwardly) extrapolated survival during the
stable period at the time of exacerbation onset. The 95% confidence intervals (CI) of the estimated
case fatalities were obtained by bootstrapping. A random effect model was used to combine all
estimates into a weighted average with 95% CI.
The meta-analysis based on six studies that fulfilled the inclusion criteria resulted in a weighted
average case-fatality rate of 15.6% (95% CI 10.9–20.3), ranging from 11.4% to 19.0% for the
individual studies.
A severe COPD exacerbation requiring hospitalisation not only results in higher mortality risks
during hospitalisation, but also in the time-period after discharge and contributes substantially to
total COPD mortality.
KEYWORDS: Case fatality, chronic obstructive pulmonary disease, exacerbation, hospitalisation,
meta-analysis
W
orldwide, mortality due to chronic
obstructive pulmonary disease (COPD)
is high. According to the World Health
Organization, at least 2.7 million deaths every year
are due to COPD [1]. The 30-yr projections from
the Global Burden of Disease Study show a
striking increase in COPD as a cause of death to
the third place worldwide in 2020 [2]. This
increase largely results from a worldwide increase
in the prevalence of smoking, especially in the
developing countries and among females, and
ageing of the population. The excess mortality
among patients with COPD is high, not only
because of the presence of COPD but also because
of the increased prevalence of other smoking-
related diseases [3].
Many studies have analysed predictors of mor-
tality in COPD. Among the factors independently
associated with mortality in COPD are age, lung
function (forced expiratory volume in 1 s and
inspiratory capacity divided by total lung capa-
city), dyspnoea, comorbidity, body mass index
(BMI), fat-free mass, exercise capacity, arterial
oxygen tension, C-reactive protein, the BODE
index (BMI, the degree of airflow obstruction,
dyspnoea and exercise capacity), airflow obstruc-
tion, dyspnoea and exercise capacity, and the
number of previous hospitalisations [4, 5].
Because patients with COPD are often recorded
as dying from other causes, it has been suggested
that all-cause mortality is probably the best mor-
tality measure to use in COPD [5]. Nevertheless,
it is well known that many patients dying do so
during a severe COPD exacerbation, when they
experience acute respiratory failure [6]. However,
there is a relative scarcity of knowledge on mor-
tality rates from COPD exacerbations. Unlike in
myocardial infarction and stroke [7], no estimates
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of the case fatality of a COPD exacerbation exist. This may
be associated with the absence of consensus on the length
of the critical period during which the mortality risk is
increased.
The most frequently reported outcome of death due to COPD
exacerbations is short-term, in-hospital mortality [8]. Previous
studies have estimated in-hospital mortality after hospitalisa-
tion for a COPD exacerbation to range from 2.5% to 14% [9, 10].
Mortality among patients admitted to intensive care units
(ICUs) is much higher, i.e. up to 30% [11]. In-hospital mortality
is insufficient to assess case fatality for at least two reasons.
There is a selection bias towards patients with longer hospital
stays and it does not incorporate the mortality that occurs after
hospital discharge but is still attributable to the index
exacerbation. Therefore, our study aimed to estimate the case
fatality of a severe COPD exacerbation including the time-
period after hospitalisation. This study arose out of our need to
capture the impact of exacerbations on mortality within the
context of a dynamic, COPD progression model [12, 13] used to
evaluate the impact of different COPD interventions. To fully
simulate the potential long-term impact of interventions which
successfully prevent or treat exacerbations, the impact of
severe exacerbations on mortality needed to be estimated. As
the COPD population in the model is specified by age, which is
a significant predictor of mortality in COPD [5], we also
investigated the association between age and mortality after a
severe exacerbation.
METHODS AND MATERIALS
We performed a comprehensive literature search in MEDLINE
and EMBASE for journal articles published after 1990 reporting
mortality or survival during and after hospitalisation for an
exacerbation of COPD using the MESH (sub)headings ‘‘chronic
obstructive pulmonary disease or COPD or chronic bronchitis’’
in combination with ‘‘mortality or dead or death* or life
expectancy or survival or prognosis’’ and ‘‘hospital* or
admission* or admitt* or exacerbation* or disease episodes’’.
We also searched references listed from articles retrieved.
Studies were excluded if the patient population was a
subgroup of hospitalised COPD patients, such as patients
requiring mechanical ventilation. Inclusion criteria were: a
European, American or Australian study population; a follow-
up period that started at hospital entry and lasted o1.5 yr; and
presenting mortality rates at three or more time-points after
hospital admission, or presenting a survival curve. Studies that
fulfilled all inclusion criteria except for a follow-up of 1.5 yr or
the presence of three data points were used to complete the
information on the average mortality rates at different time-
points after a severe exacerbation as presented in the literature.
In addition to information on the average mortality rates at
different time-points, data on the association between mortal-
ity and age was extracted from the studies.
Our general approach was as follows (fig. 1). For each study
we extracted the survival curve presented in the article or
estimated the curve from the presented data ourselves. We
roughly distinguished between the critical and the stable
period after hospital admission with the survival curve during
the stable period being flatter than the one during the critical
period. Several data points from the curve during the stable
period were extracted to estimate survival during this period.
Only data points well after the critical period were included.
For each study the survival function during the stable period















FIGURE 1. Survival curve after hospitalisation for an exacerbation of chronic








References rejected based on:
  Title review: not relevant (n=24)
  Country of the study population (n=12)
  (not European, American or Australian)
References rejected based on:
  Not reporting the associated between
  hospitalisation for COPD and mortality
  (n=13)
  Exclusion of patients dying during the
  hospitalisation (n=8)
  Patient population was subgroup of all
  hospitalised COPD patients (n=13)
  Same study population already included
  in the meta-analysis (n=10)
Studies which follow-up was too short to
estimate the case fatality that were used 
to complete the information on mortality 
rates at different time-points after a 








Studies included in 
the meta-analysis
(n=6)
FIGURE 2. Results of the systemic literature search. COPD: chronic
obstructive pulmonary disease.
M. HOOGENDOORN ET AL. COPD
c







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































COPD M. HOOGENDOORN ET AL.
510 VOLUME 37 NUMBER 3 EUROPEAN RESPIRATORY JOURNAL
S(t) 5 (1-g) Exp[- a t - b t2]
With t being the time, t50 being time of hospital admission,
S(t) the survival probability, a and b the parameters that define
the nonlinear change in survival over time, and g the case
fatality of the exacerbation.
The survival curve was fitted by minimising the sum of
squared differences with the points that were extracted from
the curve, or given in the publication. We then extrapolated the
survival curve during the stable period back to the time of
hospital admission and calculated where the curve intersected
the vertical axis (i.e. the start of hospital admission). The case
fatality was defined as the excess mortality that results from an
exacerbation and equals: g51-S(0). Uncertainty intervals for
each parameter were obtained from bootstrapping. Based on
the given initial sample size and the calculated survival
probabilities for each interval during the follow-up period,
we randomly draw new survival numbers assuming binomial
distributions. In this way we generated new survival curves,
resulting in newly calculated values for the model parameters.
The 2.5% and 97.5% percentile values correspond with the 95%
uncertainty interval. Finally, estimates from all studies were
combined to calculate the weighted average for g, using
random effect meta-analysis [14]. The weights were based on a
combination of the sampling error (variance of case fatality
within each study) and the random-effect variance (variance of
case fatality between all studies).
To estimate the association between age and mortality after a
severe exacerbation, the relative risks of age on mortality
within a study, if reported, were extracted from the retrieved
references. The association with age within each separate study
was investigated because there was little difference in the
mean age between the different studies. The weighted average
relative risk was calculated using the variance in the individual
studies as a weight.
RESULTS
After the first selection, 60 references were obtained in full
(fig. 2). An entire review of these remaining publications
resulted in the exclusion of another 44 studies for different
reasons (fig. 2). The main reasons for exclusion were that the
association between hospitalisation for COPD and mortality
was not reported (13 studies) and that the study population
consisted of a selective subgroup of hospitalised patients
(13 studies). Of the latter 13 studies, six studies included
patients admitted to ICU or requiring (non)mechanical ventila-
tion only, three included patients treated in the emergency room
or pre-hospital setting only, two included hospitalisations for
diagnoses other than COPD, while two studies included
patients with a first admission or a very mild exacerbation
only.
Of the remaining 16 studies, 10 studies met all inclusion
criteria except for the 1.5 yrs of follow-up. Hence, a total of six
studies were finally included in the meta-analysis to calculate
the case fatality rate [15–20]. None of these studies evaluated
the effect of an intervention as they were all cohort studies. For
one of these six studies, the study of BREKKE et al. [20], we had
access to the patient level data. For the other five studies
results were based on the data presented in the article.
Characteristics of the included studies are shown in table 1.
Case fatality
Table 2 presents the results of the curve fitting procedure for
each of the selected six studies. Details about the parameter
values for each study are presented in the supplementary data.
The estimated average case-fatality rate for the individual
studies varied between 11.4% and 19.0%. The overall weighted
mean value of the case fatality of an exacerbation was 15.6%
(95% CI 10.9–20.3%).
Association between mortality and age
All of the six studies included in the meta-analysis reported on
the association between mortality after a hospitalisation for an
exacerbation and age. Age was a significant predictor of
mortality in univariate analyses (five studies) and remained an
independent predictor after correction for other explanatory
variables in multivariate analyses (4 studies). On average the
probability of dying after hospitalisation for an exacerbation
increased by 4.1% per year increase in age (RR 1.041, 95% CI
1.037–1.045) (six studies).
Average mortality rates at different time-points presented in
the literature
Characteristics of the 10 studies with an insufficient length of
follow-up are shown in table 3 [9, 10, 21–28]. Table 4 shows the
average mortality probabilities at different time-points for
these 10 studies as well as the six studies that were included in
the meta-analysis. Based on all 16 studies combined, the
average in-hospital mortality rate was 6.7%. The average
mortality rates at 3 and 6 months were 18% and 26%,
respectively.
DISCUSSION
In this study the case fatality of an exacerbation was calculated
by extrapolating the survival curve during the stable period to
the time of exacerbation onset. The weighted average case-
fatality rate was estimated to be 15.6%, with the individual
studies varying from 11.4% to 19.0%. The average in-hospital
mortality rate was 6.7%, which strongly supports the notion
that the critical period indeed exceeds the duration of the
hospitalisation.
TABLE 2 Estimated case fatality of a chronic obstructive
pulmonary disease exacerbation
First author [ref.] Patients n Estimated mean case fatality %
(95% CI)
CONNORS [15] 1016 17.2 (11.5–23.1)
VESTBO [16] 487 12.3 (5.8–18.4)
GROENEWEGEN [17] 171 17.7 (10.2–25.8)
GUNEN [18] 205 16.7 (7.9–25.4)
MCGHAN [19] 54269 11.4 (10.6–12.2)
BREKKE [20] 996 19.0 (18.7–19.3)"
Overall estimate# 15.6 (10.9–20.3)
#: Overall weighted average case fatality based on random effects analysis;
": based on patient level data.
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However, we would like to emphasise that the estimated case
fatality can not be compared with the mortality rates at
different time-points as these represent different concepts. The
case fatality was calculated as one minus the survival that
would have been expected if the patient would have been
stable (fig. 1), while mortality at a certain time-points was
calculated as one minus the survival at that specific point in
time. This also implies that the exact distinction between the
critical and stable period after exacerbation onset, however,
could not be determined by comparing the case-fatality rate
with mortality rates at different points in time. The critical
period was defined as the period in which mortality is
increased compared to the stable situation. Therefore, this
period ranges from the hospital admission until the point were
the estimated survival curve during the stable period
approaches the actual observed survival curve (fig. 1).
Estimating the point where the two survival curves approach
each other is only possible if patient-level data are available or
when we make additional assumptions on how the case
fatality changes over time within the critical period. We had
patient-level data from one study, the study of BREKKE et al.
[20]. For this study the critical period was estimated to last
4.4 months. The length of the critical period is likely to vary
according to the population studied; in patients with several
comorbidities the exacerbation may have both more severe
[9, 19] and longer lasting impact and similarly the critical
period could last longer in the elderly.
Due to limited data and the homogeneity of the different studies
we were not able to specify the case fatality by subgroups, such
as COPD severity (defined by lung function), sex or age.
Therefore, we searched for information about the association of
these variables with mortality within the extracted studies.
Within the studies the relationship of mortality due to an
exacerbation with disease severity or sex was less clear. Mortality
after hospitalisation for an exacerbation was, however, highly
dependent on age (RR 1.041 per increase in year of age).
As the study populations of the six studies selected for the
meta-analysis were almost the same with respect to the mean
age, 65–71 yrs, age did not influence the between-study
comparison of case fatalities. The studies included have
sampled data spanning a time-period of .10 yrs but no
obvious pattern of change over time in case fatality can be
seen. This could be the result of the variation in treatment and
management between the different countries but was actually
also observed in one of the included studies [16]. In contrast, a
recent study found indications of a slight improvement of
exacerbation-related mortality over time [29].
Despite the homogeneity between the studies with respect to
age, the study populations may have differed on other aspects.
Although we selected studies from Western countries, the
criteria used for hospitalisation, for example, are not similar
across countries. This is related to local treatment patterns, which
in turn may be driven by local guidelines, medical traditions,
TABLE 4 Mortality rates after hospitalisation for a chronic obstructive pulmonary disease exacerbation at different time-points for
the six studies included and the 10 studies excluded from the meta-analysis fulfilling all inclusion criteria except follow-
up .1.5 yrs
Patients n Mortality rate %
In-hospital 3 months 6 months 1 yr 2 yrs 5 yrs
Studies included in the meta-analysis
CONNORS [15] 1016 11 NR 33 43 49 NR
VESTBO [16] 487 NR NR NR NR NR 44
GROENEWEGEN [17] 171 8 16 18 23 NR NR
GUNEN [18] 205 8.3 NR 24 33 39 NR
MCGHAN [19] 54269 3.6 NR NR 24 NR 57
Brekke [20] 996 9.9 22 27 32 41 NR
Studies excluded from the meta-analysis#
FUSO [10] 590 14 NR NR NR NR NR
CYDULKA [21]" 131974 6 NR NR NR NR NR
ERIKSEN [22] 300 8.6 19 NR 36 NR NR
PATIL [9] 71130 2.5 NR NR NR NR NR
YOHANNES [23] 104 3.8 NR NR 38 NR NR
WANG [24] 282 9.9 NR NR NR NR NR
PRICE [25] 7529 7.4 15 NR NR NR NR
BUSTAMENTE [26] 763 6.4 NR NR NR NR NR
KINNUNEN [27] 728961 3.2 NR NR NR NR NR
DRANSFIELD [28] 825 5.2 NR NR NR NR NR
Overall estimate based on all
16 studies % (95% CI)+
6.7 (5.7–7.7) 18 (14–22) 26 (20–32) 33 (25–40) 43 (37–50) 51 (38–63)
NR: not reported. #: follow-up ,1.5 yrs; ": results year 1991; +: overall weighted average mortality rates based on random effects analysis; 1: number of admissions
instead of number of patients.
M. HOOGENDOORN ET AL. COPD
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 37 NUMBER 3 513
cultural aspects, financing and reimbursement schemes, etc. In
our selected studies the mean length of stay was significantly
longer in the European studies compared to studies from the
USA, 11 days versus 7 days. However, the mean in-hospital
mortality rate did not differ. One study aspect which seemed to
have an influence on the results was whether or not patients
included in the study had physician- or spirometry-confirmed
COPD. Studies including patients with confirmed COPD
reported higher mortality rates than studies including patients
with hospitalisation for COPD based on International Classi-
fication of Disease (ICD) coding. The mean in-hospital mortality
rate for both groups were 9.2% (95% CI 7.4–10.9%) and 4.8%
(95% CI 3.5–6.1%), respectively. Two of the studies used in the
meta-analysis included patients with a hospitalisation for COPD
based on ICD coding. If the largest of these two studies, the study
of MCGHAN [19], was excluded from the meta-analysis, the
average case-fatality rate would have been higher, i.e. 17.9% (95%
CI 15.8–20%). Studies using ICD coding only to define COPD
may report lower mortality rates because they also included
mild patients or patients with, for example, asthma that were
wrongly coded.
In conclusion, mortality in COPD is common and severe
exacerbations of COPD are one of the major causes of death in
COPD. In this study the case-fatality rate of a severe exacerba-
tion resulting in hospitalisation was estimated to be 15.6%,
showing the substantial impact of exacerbations on mortality.
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